Patients & Caregivers
Blibsibimod Given Orphan Designation for IgA Nephropathy
The company will share data later this month regarding their Phase 2 clinical study assessing blisibimod in patients with IgA nephropathy.
New Drug Could Dramatically Lower Wait Time for Organ Transplant
24 of the 25 HLA-sensitized patients had normalized kidney function 6 months after their transplant.
Are Corticosteroids Safe to Use in IgA Nephrology Patients?
After evaluating 262 patients given methylprednisolone, they stopped the study based on the safety profile that emerged.
Amicus Getting Ready to Submit NDA for Migalastat to Treat Fabry
Former Yankee Steps to the Plate for IPF Awareness This Father's Day
Bernie Williams, former centerfielder and 4-time World Series champion, is teaming up with Boehringer Ingelheim to raise awareness of the idiopathic pulmonary fibrosis (IPF).
Dr. Jason Kovacic Explains the Define-FMD Study
The "Define-FMD" study is comparing the genetic makeup of fibroblasts from FMD patients to those from non-FMD patients.
Fibromuscular Dysplasia in Children: Dr Kevin Meyers Explains
Kevin Meyers, MBBSc, of the Children's Hospital of Philadelphia (CHOP) talks about the incidence and symptoms of fibromuscular dysplasia (FMD) in children.
Patient and Doctor Celebrate 50th Anniversary of Kidney Transplant
Tommy's transplanted kidney is, if not the longest, one of the longest functioning live donor kidneys in U.S. history.
Diagnosing Fabry Disease in Women
Elizabeth Smith of Emory University talks about her abstract involving 3 women suspected of having Fabry disease who underwent further genetic testing.
Sneak Peak at the 24 Month Patisiran — Amyloidosis Study
Just got a sneak peak of the data Alnylam will be presenting next week at the XV International Symposium on Amyloidosis in Uppsala, Sweden.
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
RARE DISEASE INFOGRAPHIC >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.